Archive for the ‘Genetic Testing’ Category

Your genetic history reveals a great deal about you, such as your eye color and your ancestry. Your genetic make-up can also provide clues about your health, including your risk for certain types of cancer. This is done through genetic testing, which is a type of medical test that identifies changes in chromosomes, genes or proteins.

The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a persons chance of developing or passing on a genetic disorder.

Genetic counseling is a one-to-two hour consultation with a licensed genetic counselor. During this consultation, the counselor will analyze your family cancer patterns, explain how genes are inherited and explain the difference between hereditary and sporadic cancer. You also will discuss the ethical, legal and social implications associated with genetic testing to help you decide if the benefits of genetic testing outweigh the risks, including emotional, social and financial risks.

One of the biggest misconceptions about genetic testing for older adults is that someone is too old for it to be beneficial. Since health professionals are looking for genes you have had since you were born, youre never too old for genetic testing.

Regardless of age, if you have cancer, finding out if you carry a predisposition for that cancer could potentially help your oncologist determine the best course of treatment for you. The results can also tell your healthcare provider what other cancers you may be at risk for and discuss screening and surgical options to reduce that type of cancer.

If you have been previously diagnosed with cancer, genetic counseling/testing can help determine if your diagnosis has a hereditary component. This information can lead to specific medical management recommendations and can determine if your family members may have similar hereditary risks.

If you have not been diagnosed with cancer, genetic counseling can help to plan the most informative testing strategy for your family.

Genetic testing most commonly looks for genes that affect risks for breast, colorectal, ovarian, uterine, prostate or pancreatic cancers.

A consultation with a cancer genetic counselor is recommended for individuals who have any personal or family history of:

Consumer based genetic testing

Over the last decade, dozens of companies began offering consumer genetic testing for a variety of purposes. Some companies combine this service with ancestry testing and some also offer a health section.

The difference with this type of test is there is no healthcare provider involved in the process and it is not as comprehensive as those offered through a healthcare provider. Genetic counselors are licensed professionals with special education and training who interpret the genetic test results and provide you with an individualized cancer risk analysis. Investigating if you or your family members are at an increased risk for cancer can be overwhelming, which is why its important to have a professional guide you through this process.

Genetic counselors are experts in understanding insurance coverage for genetic testing. Each insurance company has specific criteria for coverage. Most insurance companies will cover genetic testing when it is medically recommended.

Coverage for genetic testing can only be determined after a full evaluation of your medical and family history by a genetic counselor and will be explained to you before you decide whether or not to undergo testing. Here are some general insurance guidelines:

If youre interesting in genetic testing, talk to your primary care physician or schedule an appointment with a licensed genetic counselor at the MemorialCare Todd Cancer Institute at Long Beach Medical Center by calling 562-933-RISK (7475).

See the rest here:
Senior Living: Your genes tell a story that can be passed down for generations - Press-Enterprise

The Parkinsons Foundation has expanded its PD GENErationnational study to include at-home genetic testing and virtual counseling inSpanish as well as English.

Opened in 2019 through the organization and partly supported by Biogen, PD GENEration offers Parkinsons (PD) patients free genetic testing plus genetic counseling to help them understand test results.

To remove barriers to Parkinsons research participation in the underserved Hispanic population, the Parkinsons Foundation decided to offer patientsat-home testing and counseling in Spanish. The study seeks to use the testing to boost clinical trial enrollment. In turn, researchers hope to use test results to develop treatment candidates and personalized therapeutic approaches.

We want the Hispanic community to know that they can be empowered by taking part in the PD GENEration program and that their voices and experiences are incredibly valuable in helping us move the field forward for the entire PD community, said Ignacio Mata, PhD, chair of the Parkinsons Foundation Hispanic Parkinsons Advisory Council, in a press release.

Offering the study in Spanish is critical to ensuring that the Hispanic community can easily participate and therefore will be well represented in this important study, Mata said.

After a virtual screening appointment to confirm eligibility, prospective PD GENEration participants schedule a two-hour virtual testing appointment. During that appointment, and with guidance from a healthcare professional, patients complete the genetic assessment.Test results are discussed with a counselor during a follow-up phone appointment.

To determine participation eligibility, go here for a short online questionnaire. For questions about enrollment, write to [emailprotected].

The Parkinsons Foundation has adapted to help the PD community gain access to this valuable and empowering information from the safety and comfort of their homes during the ongoing COVID-19 pandemic and beyond, said James Beck, PhD, the organizations chief scientific officer. We are looking forward to continuing this research study so that we may one day soon be able to provide precision treatments for the 1 million Americans living with Parkinsons disease.

Genetic testing and counseling will remain available at six in-person testing sites nationwide. The Foundation expects to add 10 testing sites next year.

In addition to identifying potential clinical trial participants, such testing can help scientists uncover underlying Parkinsons mechanisms, which could lead to improved treatments and patient care. Understanding genetic differences across people with Parkinsons can help reveal the diseases variable effect.

As it stands, genetic tests for Parkinsons often are unaffordable and not covered by insurance. And, many dont offer genetic counseling, which can help interpret test results. Consequently, most Parkinsons patients dont know whether they carry genetic changes in Parkinsons-related genes. The PD GENEration study seeks to address this need.

Early study results show that comprehensive genetic testing and counseling, and the identification of rare genetic mutations linked to the disease, is practicable for the Parkinsons community at large.

Roughly 15% of Parkinsons cases may be associated with genetic mutation.Since its launch, the PD GENEration study has tested at least 291 people, 52 of whom tested positive for a Parkinsons-related mutation.

The study tests for the following genes with known Parkinsons associations: GBA(glucocerebrosidase beta),LRRK2(dardarin),PRKN(Parkin),PINK1(PTEN induced putative kinase 1),PARK7(DJ-1),VPS-35,andSNCA(alpha-synuclein).

To date, some study participants tested have shown extremely rare mutations, with some individuals even carrying multiple Parkinsons-associated mutations. This information should contribute to a better understanding of the neurodegenerative disorder.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours dElegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled Belle of the Concours.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

Original post:
PD GENEration Study Now Includes At-home Genetic Testing and... - Parkinson's News Today

This article was originally published here

JCO Oncol Pract. 2020 Sep 28:OP2000431. doi: 10.1200/OP.20.00431. Online ahead of print.

ABSTRACT

Germline genetic testing is now routinely recommended for patients with prostate cancer (PCa) because of expanded guidelines and options for targeted treatments. However, integrating genetic testing into oncology and urology clinical workflows remains a challenge because of the increased number of patients with PCa requiring testing and the limited access to genetics providers. This suggests a critical unmet need for genetic services outside of historical models. This review addresses current guidelines, considerations, and challenges for PCa genetic testing and offers a practical guide for genetic counseling and testing delivery, with solutions to help address potential barriers and challenges for both providers and patients. As genetic and genomic testing become integral to PCa care, developing standardized systems for implementation in the clinic is essential for delivering precision oncology to patients with PCa and realizing the full scope and impact of genetic testing.

PMID:32986533 | DOI:10.1200/OP.20.00431

View original post here:
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics...

Megan Henry|The Columbus Dispatch

Joan Swarts recently learned she has a greater risk of developing colon, ovarian and breast cancer.

Genetic testing counselors at OhioHealth were able to discover all of this information after taking ablood sample from her back in February.

Now, Swarts, 55, of Delaware,is being proactive. She recently met with a colorectal surgeon and knows to increase the frequency of her colon screenings.

Im glad that I now know thats a potential and I can take steps to watch for that to catch it early, she said.

Genetic testing recognizes changes in chromosomes, genes or proteins. The results can help confirm or dismiss a suspected genetic condition;help determine a persons chance of developing a genetic condition; and show the likelihood of passing on a genetic disorder, according to the National Library of Medicine.

What we hope is that the genetic testing information is going to give us a very personalized plan for what that person needs to do based on their genetic testing results and based on their family history, said Amy Sturm, a cardiovascular genetics expert for the National Society of Genetic Counselors.

Test results come back either positive (meaning the test found a genetic change known to cause disease),negative (meaning the test did not find a genetic change known to cause disease), oruncertain (meaning there isn't enough information about the genetic change to figure out if it's normal or could cause a disease), according to the Centers for Disease Control and Prevention.

The results can answer questions like, Are there things that I can do that will enable me to not develop this disease? Or that can basically modify my risk or things that I can do to prepare myself for what might come in the future because I have this genetic condition? said Nichole Morman, genetic counseling manageratOhioHealth.

The number of licensed genetic counselors in Ohio has been on the rise. There were 221 in 2016 and 423 in June of this year, according to the state medical board annual report.

People do genetic testing for a variety of reasons. Somemight wonder whether they are predisposed to a genetic condition if they have a family history. Or a person might want to know why they were diagnosed with a specific condition. They might also question whether they could pass on a genetic condition to a child.

Breast cancer runs in Swarts'family. Her grandmother died from breast cancer when she was 65, so Swarts'breast health doctor urged her to do genetic testing.

(The genetic testing)was really informative,"Swarts said."I felt like I was inundated with a lot of information but everything has been explained really well to me as far as preventive things I need to do.

Erin Pettegrew, 46, did genetic testing a couple of years ago after her mom was diagnosed with ovarian cancer seven years ago.

TheHilliard resident had the tests through the Making Genetic Testing Accessible (Magenta) study, an at-home screening for 19 genetic abnormalitieslaunched out of the University of Texas MD Anderson Cancer Center.

She saw an ad for Magenta pop up on her Facebook and sent in her cheek swab after getting the kit. She got her results back a few weeks later saying she didnt have a genetic predisposition to ovarian cancer.

My heart was pounding as I opened the email for sure, but once I saw that it was negative it was a big relief, Pettegrew said. If it had been positive, I would have had to make some choices about maybe having my ovaries removed early in life and other considerations about my own health, but I didnt have to go down that path."

There is a psychological aspect tofinding out whether you're predisposed to a genetic condition, Morman noted.

How is that going to make me feel about myself? How is it going to impact my relationships with my family members?" Morman said.

Swarts's mind is more at ease knowing she has the potential for these diseases and she takes comfort knowing it can be caught early.

"Honestly, Im one of those people who thought I really dont want to know so I was nervous about doing it, but Im glad I did so I can take the necessary measures to look for this stuff,"Swarts said.

Direct-to-consumertesting like 23andMe is also an option, but the results can be limited.

If you are interested in doing genetic testing because of a family health history of a certain disease, we do not recommend doing a 23andMe test, rather you should speak to your health-care provider,Aushawna Collins, 23andMe spokesperson, said in an email.

Genetic testing is continuing to evolve and whole-genome sequencing for newborns could be on the horizon.

A baby is born and you want to know for that baby's entire life what might they be at risk for, Sturm said. I think really getting that full genome sequencing at a very young age and then using it as a resource throughout their life is something we really are striving toward in our field.

mhenry@dispatch.com

@megankhenry

Original post:
Genetic testing helps patients be proactive in seeking healthcare - The Columbus Dispatch

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations.

Addressing gaps in testing and education within precision oncology can assist in improving access to patients of color and other underserved populations, said Karen Winkfield, MD, PhD, incoming executive director, Meharry-Vanderbilt Alliance.

Transcript

AJMC: In the era of precision medicine, what can oncologists do to ensure that newer therapies are the right choice for minority patients?

Dr Winkfield: Precision oncology has really come a long way, and I do think that oftentimes people think about it as just genetic testing or genomic testing. That's important, and we do know that there's a gap, even in terms of testing, for some things as simple as an oncotype for breast cancer patients. We know that Black patients are not getting the oncotype test at the same rate as other racial and ethnic groups.

So, really, just making sure that there's access is one thing that can be important. Whether it be partnering with some of the testing facilities to make sure that there is opportunity for individuals who may be underinsured or uninsured to gain access to some of these precision oncology tests, that would be wonderful.

The other thing is making sure people understand, again, community engagement. I'm going to keep coming back to that, because patients need to understand the importance of it and know that they're not being a guinea pig, etc, but that we want to make sure that their treatment is personalized. The personalization is not just to them as an individual, but also to their tumor and what their tumor might be doing. So, that communication is important as well.

So, sometimes it may require a second biopsy. So, you can imagine, if a person has gone through therapy and then their tumor is not responding, and you say, "Oh, we need to get some more tissue," there can be some misunderstandings about that. So, really being open with your patients about the rationale and the reason for getting additional tissue, but, again, making sure that patients don't have very high out-of-pocket cost is one of the things that I think will go a long way to improving access to patients of color and other underserved populations to precision oncology.

Read the original post:
Dr Karen Winkfield on Improving Minority Access, Education for Precision Oncology - AJMC.com Managed Markets Network

ALISO VIEJO, Calif., Oct. 1, 2020 /PRNewswire/ --Ambry Genetics(Ambry), a leading clinical genetic testing lab, is launching its CARE for COVID Program with Western Springs School District 101 and The Green Alliance International. The Ambry Genetics Comprehensive, Assessment, Risk, and Education (CARE) for COVID Program is designed to help identify and test individuals in need of coronavirus testing. The program provides Western Springs School District 101 with the system, tools, and support needed to screen and test their faculty and other employees as they return to their offices and classrooms this fall. The Western Springs School District, located in a suburb of Chicago, Illinois, serves students from kindergarten to eighth grade. The Green Alliance International will be using the CARE for COVID Program's screening and exposure questionnaire as part of their Gateway Entry Systems program. The Gateway Entry Systems program provides school systems, sports venues, and businesses across the U.S. with the tools needed to safely reopen, including disinfecting technology, wristband body temperature screening, and the CARE for COVID program's symptom and exposure digital questionnaire for remote monitoring.

The CARE for COVID program includes viral testing by RT-PCR for individuals who are exhibiting symptoms or have known exposure, with results returnedwithin 24-48hours of receipt of the sample. Ambry's RT-PCR test uses saliva collection and creates a simpler and more convenient experience than the nasopharyngeal swabs commonly used by other labs.

The CARE for COVID Program also includes:

The robust, one-stop nature of the CARE for COVID Program ensures that individuals are not missed through multiple engagement points. The CARE for COVID Program incorporates the latest guidance from federal agencies, including the CDC. Ambry worked directly with noted experts in academia, industry, and government to develop the program.

"Over the last six months or so, our team has worked tirelessly to transition our lab and the CARE Program into a comprehensive, end-to-end solution to support workforce and community testing efforts," Ambry Genetics CEO Aaron Elliott said. "We look forward to helping more businesses and schools to safely reopen."

Ambry is expanding the CARE for COVID Program to other school districts and businesses this fall. The Program can be tailored depending on the organization's needs, and employers can choose the frequency for asking individuals to complete the screening questionnaire, whether daily or less often. Ambry is contracted with health plans representing over 90% of insured individuals, making it convenient for the employers to bill insurance for the testing performed.

"With the development of our CARE for COVID program, we learned that organizations want an end-to-end solution," Ambry Genetics Chief Commercial Officer Tom Schoenherr said. "If a critical component is missing in the solution, it will not work. The CARE for COVID program includes education, evaluation, assessment, counseling, testing, post-test counseling, workplace exposure tracing, and reporting."

The Ambry CARE program is a population-health, precision-medicine tool that can address employee health and wellness across a range of medical issues. Already used to help people learn whether they are at risk for hereditary cancers including, breastand colon cancers, the program can also be adapted to help identify and manage diabetes, cardiovascular, and other diseases. To learn more about the CARE program and hereditary cancer risk, please visitambrygen.com/care.

ABOUT AMBRY GENETICS

Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions. For more information, please visitambrygen.com.

For more information on risk factors for hereditary cancer, please visit cancer.gov's fact sheet on hereditary cancer and genetic testing.

Press Contact:Liz Squire[emailprotected](202) 617-4662

SOURCE Ambry Genetics

See the article here:
Konica Minolta Precision Medicine (KMPM) Company Ambry Genetics Announces Comprehensive COVID-19 Screening, Management, and Testing Program To Help...

Wouldnt it be great to know the optimal diet that successfully makes you lose weight? Or understand your skins natural ability to combat wrinkles and be able to strengthen that ability? Or even better, detect that you have a high risk of cancer and be able to prevent rather than treat it?

The good news you can do all these things and more all it takes is a simple saliva swab.

Were talking aboutCircle DNA, the worlds most comprehensive DNA test that delivers over 500 personalised reports on categories such as disease risk, food sensitivity, and even your personality and behavioural traits. Its backed by Chinese stars G.E.M., Gigi Leung, and Vanness Wu, and it might just be the health and wellness solution of the future.

We decided to delve a little deeper and met up with CEO and Co-founder Danny Yeung to find out more. Read on to discover how he started, what it takes to be in the genetic-testing industry and most importantly, does it actually work?

Circle DNA is was started out in 2014 as a university spin-off, by team of professors focused in genetics and clinical research. The team of 150 consists of scientists, engineers, genetic counsellors, health coaches and more; and we have officesin London, Singapore, Hong Kong, Kuala Lumpur, Johannesburg, and more.

With a simple saliva sample you can uncover different things about yourself your genetic blueprint. Things like how to optimise your diet and nutrition, stress profile, pharmacogenetics (your response to drugs), as well as more serious items related to health. It can identify your genetic risk for cancers and diseases: dementia, Alzheimers and Parkinsons. Even for family planning: if youre looking to have a child, you can check if you or your partner have any genetic conditions that may or may not pass on to your unborn baby.

You can have a full profile of yourself so you can understand what you need to watch out for, areas that need attention and areas that can be optimised its optimised wellbeing.

We are focused on health and prevention. We believe everyone should have the power to understand this information. And once you have this information, this is where you can make changes to your diet and lifestyle, ultimately delaying diseases and cancers.

Circle of life! Its our direct consumer genetics testing brand, so we wanted to have a name that people would relate to and can remember, and ultimately understand what we do straight away.

The best days are when we launch a product, or when we interview passionate potential employees that eventually join us. New partnerships or distribution deals, too. These are good days. But I do think that we make good progress every day, so I guess, theyre all good days. Ultimately what drives us is that we are making a difference for society. Were making a difference to someones health, to their family and potentially the next generation.

I dont know if there is a worst day. I have a very optimistic viewpoint naturally. Its something that comes with being an entrepreneur, I think. Every day has its ups and downs; the challenge is how you get through them.

When Im not at work, I like to spend time with my daughter. Shes five years old. We like to take her out to play. Recently, weve been spending a lot of time on the South Side and we go to the beach.

Not really. As an entrepreneur, you always have to be switched on. So throughout my life, or at least in the last 15 years since becoming an entrepreneur, its been a big part of me, always making sure Im available. So I never switch off fully.

I look at things with a very logical and optimistic perspective so I dont get stressed much, either. I try not to dwell on things, especially things I cant control.

Everything that we have done is part of the learning process. Do I regret anything? No. Were moving in the right direction. The reason we launched Circle (DNA) now, as opposed to 4, 3 or 2 years ago, is because health and wellness has only become a much bigger topic in the last year or two. People are more aware now. So launching now, people already have a good idea.

In the health industry, you have to be a little more patient. It takes time to gain traction. Also, there are certain regulatory aspects, government approvals, lab certifications and a lot of different things that you have to do properly. At the end of the day, its about peoples health, so you want to make sure youre doing everything you can to make sure youre providing the best information to people.

Also, you need to have different stakeholders. Different partners. People that can help get the word out about health. You need to have different parties involved.

Lastly, find out your unique selling proposition, whatever business youre in. If you dont have one, then you shouldnt go into business. A lot of people dont realise that.

Actually, I always wanted to be an entrepreneur. I knew that I wanted to have my own business. I didnt know that it would be this, but I knew I wanted to do my own thing. Thats why I started working really young. I started when I was 15! Or at least thats when I was getting paid. I started working at a baseball card shop when I was 12 and the owner paid me in baseball cards.

I wouldnt say hurdle, but the biggest challenge, even now, is education. Theres still a lot of misinformation about what genetic testing can do. Theres are people who are like, I dont want to know because they think its like a paternity test. But the technology has evolved to be much more than that, so awareness and education for genetic testing is still very important.

Weve been able to do that somewhat, and have utilised three celebrities G.E.M., Vanness Wu and Gigi Leung who have come on board as our ambassadors. G.E.M., who is also an investor of the company, is putting her own personal name on it. It helps to create awareness, but its a continuous challenge. Were still quite new to this space. I mean, in the US, roughly 8% of the population have done a genetic test. Here, in Asia, its only about 0.08%. So you can see the growth opportunity is massive.

I think there are a lot of innovations in health and AI. Better solutions. There is still a lot of opportunity here. For instance turning something invasive into non-invasive. These are areas that are worth looking into.

There may be people that already consider me successful, but I dont look at it that way. I still feel we have a very long way to go. Were maybe at 1% of where we should be, but it has been a great journey thus far. Weve been making the right strategic moves, we have the right investors, the right partnerships and the right business model. Now, we have to just scale and execute.

Ultimately we want to impact millions of people here in Asia. Once we reach a million people, then I might say, Hey, were on to something. But after that, Ill have more goals.

For our technology, the first thing to note is that we utilise whole exome sequencing, while our competitors utilise a technology called genotyping. The problem with genotyping is youre only looking at a snip of a gene. Youre not looking at the whole gene, so youre likely to miss a lot. In fact, a recentstudyrevealed that genotyping companies have a 85% false positive rate. Which means if they provide any positive results, 85% of the time, its wrong.

Meanwhile, our test has also been externally validated by CUHK, the Croucher Laboratoryfor HumanGenomics, for analytical accuracy at 99.9%. Accuracy to determine that gender mutation does exist in your body.

Im a prime example. About three years ago, I actually detected that I have an increased risk of colon cancer. So of course, I was quite scared and shocked because I dont have a family history of cancer. In fact, 40-50% of people who have genetic mutations do not have a history.

It was because of that risk that I modified my diet and lifestyle. I cut out red meat and lost over 20 pounds over the last 3 years. And I also started early screening at 37 years of age. I wouldnt have done it if I didnt get those results. I would have most likely waited until age 50, which is the global recommendation for screening. But for someone like me with an increased risk, that may have been too late for me.

Thats a bold statement to make, but I can certainly say that our tests can definitely delay or help people to prevent diseases and cancers, therefore saving lives.

For more information about Circle DNA, visit their websitehere.

(Main image: Unsplash, Photos: Circle DNA)

This story first appeared on Prestige Hong Kong.

Read more from the original source:
Danny Yeung of Circle DNA: Genetic testing can help prevent and reduce health concerns - Prestige Online

New RT-PCR testing partnership to supplement existing testing capabilities across Pac-12 athletics departments

SAN FRANCISCO The Pac-12 today announced a conference-wide surveillance testing partnership for SARS-CoV-2 (COVID-19) with Fulgent Genetics (NASDAQ: FLGT) as part of its on-going student-athlete health & well-being initiatives (SAHWBI) efforts. Under the partnership, Fulgent Genetics will provide RT-PCR (reverse transcription polymerase chain reaction) testing capabilities to supplement existing PCR and antigen testing capabilities across each Pac-12 athletics department. The partnership follows and is in addition to the Pac-12s recently announced partnership with Quidel Corporation for daily rapid-results testing capabilities (point-of-care).

We are excited to be partnering with a leading testing company in Fulgent to provide our athletic departments with the very best capabilities to protect the health and well-being of our student-athletes, said Pac-12 Commissioner Larry Scott. On the heels of our agreement with Quidel to provide rapid-results testing, todays announcement represents another important step in providing a safe and healthy environment for a return to competition for our student-athletes.

Dr. Doug Aukerman, senior associate athletics director for Oregon State and chair of the Pac-12 SAHWBI added: Providing additional resources at the level of what Fulgent Genetics offers is a tremendous addition for our athletics departments and staff as we continue to strive for the most secure and safe environment for our student-athletes return to play.

Routine, rapid testing is playing a key role in limiting the spread of COVID-19 and is helping to keep players, coaches and staff safe as they look to return to competition. The Pac-12 has implemented several protocols in this area, and the RT-PCR testing provided by Fulgent Genetics is an important part of this process, said Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. RT-PCR is regarded as the gold standard in COVID-19 testing, providing the highest level of sensitivity and specificity. At Fulgent, we have built technology platforms around our test to make it scalable for the Pac-12, which allows us to deliver results within 24 hours of receipt of the sample for testing. We are excited to partner with the Pac-12 and look forward to helping keep their athletic programs running safely.

Each Pac-12 institution currently has RT-PCR testing practices and protocols in place for their athletics departments. With the new partnership, Fulgent Genetics will be able to serve as a supplemental resource for each athletics department. The RT-PCR testing program from Fulgent Genetics will be driven by the new Fulgent Enterprise COVID-19 Screening Platform, which provides an end-to-end solution for routine and repeat testing, including onsite testing for student-athletes and staff, 24-hour results and mobile delivery and interface.

For more information about COVID-19 testing options from Fulgent Genetics please visit fulgentgenetics.com/COVID19.

About the Pac-12 Student-Athlete Health and Well-Being Initiative

Created in 2013, the Pac-12 Student-Athlete Health and Well-Being Initiative (SAHWBI) is a collective effort between the Pac-12 and all 12 member universities to find ways to reduce injuries, share current best practices and latest studies and conduct research to uncover new ways to keep student-athletes as safe as possible. For more information, go to Pac-12.com/health.

Aboutthe Pac-12 Conference

The Conference has a tradition as the Conference of Champions, leading the nation in NCAA Championships in 54 of the last 60 years, with 529NCAA team titles overall. The Conference comprises 12 leading U.S. universities - the University of Arizona, Arizona State University, the University of California,Berkeley, the University of California at Los Angeles (UCLA), the University of Colorado, the University of Oregon, Oregon State University, Stanford University, the University of Southern California, the University of Utah, the University of Washington and Washington State University. For more information on the Conferences programs, member institutions, and Commissioner Larry Scott, go toPac-12.com/conference.

About Fulgent Genetics

Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in todays market, which enables it to provide expansive options for test customization and clinically actionable results.

Continue reading here:
Pac-12 adds to RT-PCR COVID-19 testing capabilities with Fulgent Genetics partnership - Pac-12.com

Californias Genetic Information Privacy Act (SB 980), vetoed on September 25, 2020 by Governor Gavin Newsom, would have established obligations for direct-to-consumer (DTC) genetic testing companies and others that collect or process genetic information. Although the bill did not become law, its near enactment is another example of the growing trend towards increased government focus on genetic information.

SB 980

California may still see a DTC genetic testing law soon. Governor Newsom stated in his message accompanying the veto that he shares the perspective that the sensitive nature of human genetic data warrants strong privacy protections, but is concerned that the broad language in the bill risked unintended consequences. For example, he recognized that the opt in provisions of the bill might interfere with laboratories reporting requirements related to COVID-19 testing.

The bills veto reflects a disagreement over the details of how best to safeguard genetic information rather than disagreement with the principles of the bill. Governor Newsom is directing the California Health and Human Services Agency and the Department of Public Health to work with the Legislature on a solution that achieves the privacy aims of the bill while preventing inadvertent impacts on COVID-19 testing efforts. There is apparent appetite to get the bill passed in some form, with SB 980s author, California State Senator Tom Umberg, publicly stating he will work with the governors office to craft a new bill quickly.

The drafting and progression of SB 980 in California highlights the movement of state legislatures towards increased regulation of the collection, use, and disclosure of genetic information. If signed, SB 980 would have required DTC genetic testing companies to comply with certain privacy and data security provisions, including providing consumers with prescribed notice, obtaining consumers express consent regarding the collection, use, and disclosure of genetic data, and enabling consumers to access and delete their genetic information.

Legal Landscape

Historically, the laws and guidance surrounding genetic privacy focused on prohibiting discrimination, requiring testing of newborns for certain conditions, or requiring consent prior to conducting genetic tests. These laws have traditionally applied to insurers, employers, laboratories, and health care providers and included exceptions necessary for research, treatment, or required regulatory reporting. A number of states already have laws that broadly apply to genetic information or genetic testing and require explicit consent for the collection of genetic information, running of genetic tests, retention of genetic samples and information, and/or disclosure of genetic information.

There also appears to be a trend towards incorporating protections for genetic information into broader lawmaking efforts. In the past few years, a number of states have introduced bills, and some have passed laws, to create new genetic privacy laws or amend existing genetic privacy and breach notification laws to cover consumer genetic testing activities, strengthen notice and consent requirements, and increase the penalties for violations. Additionally, state consumer privacy laws and state biometric privacy laws are increasingly including genetic information in their definitions of protected information.

Federal Activity

Genetic data is becoming part of the federal privacy debate. For example, earlier this year, explicit notice and consent requirements for the use and disclosure of genetic information were included in a number of federal coronavirus relief bills. Federal proposals frequently include genetic information in definitions of sensitive information, such as Senator Roger Wickers bill, the SAFE DATA Act, that would create new privacy notice requirements, provide for injunctive relief, and establish a victim relief fund to compensate consumers for privacy violations.

In addition, over the past few years, federal regulators have been keeping a close eye on DTC genetic offerings. The Federal Trade Commission issued guidance on consumer genetic testing in 2017 and 2019 and the Food and Drug Administration published DTC guidance in 2018. Around the same time, a number of genetic testing companies worked with the Future of Privacy Forum to develop Privacy Best Practices for Consumer Genetic Testing Services, which sought to establish industry-based standards for genetic data generated in the consumer context.

Comprehensive Data Protection Laws

As SB 980 illustrates, there is a growing trend by state and federal law makers to increase regulation of genetic information and cover non-traditional entities like DTC companies. The market for DTC genetic testing has expanded dramatically in recent years with advances in testing capabilities, increased DTC offerings, and more people using at-home DNA tests to explore their genetic predispositions, family history, and ancestry. Advances in genetic sequencing and analysis technologies coupled with the current pandemic have highlighted the positive impact that rapid testing and identification of genetic variants can have for the identification of diseases, patient testing, and development of new treatments. At the same time, the prevalence of consumer testing and sensitivity of genetic information have also heightened public and legislator scrutiny of genetic privacy practices. Although this particular bill will not be enacted, entities that collect, use, or disclose genetic information can use this as opportunity to evaluate their current practices and prepare for likely changes ahead.

More:
California Governor vetoes bill to establish the Genetic Information Privacy Act - Lexology

Prenatal-and-Newborn-Genetic-Testing-Market

Global Prenatal and Newborn Genetic Testing Market 2020 research report presents analysis of market size, share, and growth, trends, cost structure, statistical and comprehensive data of the global market. Research reports analyses the major opportunities, CAGR, yearly growth rates to help the readers to understand the qualitative and quantitative aspects of theGlobal Prenatal and Newborn Genetic TestingMarket. The competition landscape, company overview, financials, recent developments and long-term investments related to theGlobal Prenatal and Newborn Genetic Testing Marketare mentioned in this report.

The key segments covered in this report are geographical segments, end-use/application segments, and competitor segments. The local segment, regional supply, application, and wise demand, major players, prices are also available by 2025. Global Prenatal and Newborn Genetic Testing Market are mentioned in the competition landscape, company overview, financials, recent developments and long-term investments.

Get PDF Sample Copy of the Report (Including Full TOC, List of Tables & Figures, Chart):https://www.marketinforeports.com/Market-Reports/Request-Sample/188068

Top Key players profiled in the Prenatal and Newborn Genetic Testing market report include:Roche Diagnostic, Elitech Group, Myriad Genetics, Biocartis, IntegraGen, Perkin Elmer, WaferGen Biosystem, Interpace Diagnostics, Quest Diagnostic, Bio-Rad, AutoGenomics, Abbott, Cepheid, EKF Diagnostics, Natera, Agilent Technologies, Illumina, Ariosa Diagnostics, Sequenom and More

Market Segment By Type:Array-Comparative Genetic Hybridization (aCGH)Fluorescence In-Situ Hybridization (FISH)Polymerase Chain Reaction (PCR)Market Segment By Application:HospitalsDiagnostic Organization

global Prenatal and Newborn Genetic Testing market report also highlights key insights on the factors that drive the growth of the market as well as key challenges that are required to Prenatal and Newborn Genetic Testing market growth in the projection period. Here provide the perspectives for the impact of COVID-19 from the long and short term. Prenatal and Newborn Genetic Testing market contain the influence of the crisis on the industry chain, especially for marketing channels. Update the industry economic revitalization plan of the country-wise government.

To Understand the influence of COVID-19 on the Set Screw Market with our analysts monitoring the situation across the globe. Get here sample analysis

Other Important Key Points of Prenatal and Newborn Genetic Testing Market:

Years Considered to Estimate the Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2025

Key questions answered in this report:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketinforeports.com/Market-Reports/Request_discount/188068

Key point summary of the Global Prenatal and Newborn Genetic Testing Market report:

Detailed TOC of Prenatal and Newborn Genetic Testing Market Report 2020-2025:Chapter 1: Prenatal and Newborn Genetic Testing Market OverviewChapter 2: Economic Impact on IndustryChapter 3: Market Competition by ManufacturersChapter 4: Production, Revenue (Value) by RegionChapter 5: Supply (Production), Consumption, Export, Import by RegionsChapter 6: Production, Revenue (Value), Price Trend by TypeChapter 7: Market Analysis by ApplicationChapter 8: Manufacturing Cost AnalysisChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Prenatal and Newborn Genetic Testing Market ForecastContinued

For More Information with full TOC: https://www.marketinforeports.com/Market-Reports/188068/Prenatal-and-Newborn-Genetic-Testing-market

Customization of the Report: Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]: https://www.marketinforeports.com/Market-Reports/Request-Customization/188068/Prenatal-and-Newborn-Genetic-Testing-market

Get in Touch with Us :Mr. Marcus KelCall: +1 915 229 3004 (U.S)+44 7452 242832 (U.K)Email: s[emailprotected]Website: http://www.marketinforeports.com

Read the original here:
Prenatal and Newborn Genetic Testing Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19 Impact |...

The Lieber family, based in Roxborough, was recently presented the Communications Champion Brighter Futures award by Philadelphias Department of Behavior Health and Intellectual disABILITY Services in honor of their leadership in the community and dedication to their son Ethan.

Ethan was diagnosed as deaf or hard of hearing at age 2. His family immediately sprang into action, seeking out all that he would need to be successful. They enrolled him in Clarke Philadelphias Early Intervention Program where he began his journey toward learning to listen and speak.

The Liebers wondered why Ethan had a hearing loss unlike any other family members and decided to participate in genetic testing where they learned Ethans hearing loss was likely a component of Hunter Syndrome.

Ethan is one of 500 boys in the United States with Hunter Syndrome, an extremely rare genetic disease caused by a missing or malfunctioning enzyme. Shortly after Ethan was diagnosed, the Liebers expanded their advocacy efforts nationally in partnership with Sock-it 2 Hunter Syndrome Foundation. They remain committed to advocating for life-changing research funds and are dedicated to supporting families on a similar path.

Even in the toughest moments, the Lieber family perseveres in supporting their son Ethan so that he can just be a kid, explains Judy Sexton, director of Clarke Schools for Hearing and Speech in Philadelphia.

Ethan uses hearing aids and is a recent graduate of Clarke Philadelphia where he was taught the listening, learning and spoken language skills needed to succeed alongside his peers with typical hearing. During Ethans four years at Clarke Philadelphia, his dad, Steve, was a regular in the classroom where he created STEM with Steve, a science-based curriculum that presented an engaging learning experience for Ethan and his friends at Clarke.

This fall, Ethan is continuing his academic journey in kindergarten at Stratford Friends in Newtown Square.

"The Liebers continue to embrace the support of Clarke, the Hunter Syndrome community, Childrens Hospital of Philadelphia (CHOP) and their Jewish community, explains Jeana Novak, early intervention coordinator at Clarke Philadelphia. Through their unending optimism, they have infused each of these groups with the belief that every day brings something to celebrate and something to share.

Continue reading here:
One of 500 boys with Hunter Syndrome and his family win award - Montgomery Newspapers

The report is an all-inclusive research study of the global Prenatal and New-born Genetic Testing market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive analysis of the global Prenatal and New-born Genetic Testing market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided accurate and reliable market data and useful recommendations with an aim to help the players gain an insight into the overall present and future market scenario. The Prenatal and New-born Genetic Testing report comprises in-depth study of the potential segments including product type, application, and end user and their contribution to the overall market size.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2753384&source=atm

Competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the global Prenatal and New-born Genetic Testing market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the global Prenatal and New-born Genetic Testing market, considering the key aspects such as areas of operation, production, and product portfolio. Additionally, companies in the Prenatal and New-born Genetic Testing report are studied based on the key factors such as company size, market share, market growth, revenue, production volume, and profits.

segment by Type, the product can be split intoPCRFISHaCGHNIPTMSSMarket segment by Application, split intoHospitalClinicOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2753384&source=atm

The Prenatal and New-born Genetic Testing report has been segregated based on distinct categories, such as product type, application, end user, and region. Each and every segment is evaluated on the basis of CAGR, share, and growth potential. In the regional analysis, the report highlights the prospective region, which is estimated to generate opportunities in the global Prenatal and New-born Genetic Testing market in the forthcoming years. This segmental analysis will surely turn out to be a useful tool for the readers, stakeholders, and market participants to get a complete picture of the global Prenatal and New-born Genetic Testing market and its potential to grow in the years to come.

Highlights of the Report

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2753384&licType=S&source=atm

Table of Contents Covered in the Report:

1 Prenatal and New-born Genetic Testing Market Overview

1 Prenatal and New-born Genetic Testing Product Overview

1.2 Prenatal and New-born Genetic Testing Market Segment by Type

1.3 Global Prenatal and New-born Genetic Testing Market Size by Type

1.3.1 Global Prenatal and New-born Genetic Testing Sales and Growth by Type

1.3.2 Global Prenatal and New-born Genetic Testing Sales and Market Share by Type (2015-2020)

1.3.3 Global Prenatal and New-born Genetic Testing Revenue and Market Share by Type (2015-2020)

1.3.4 Global Prenatal and New-born Genetic Testing Price by Type (2015-2020)

2 Global Prenatal and New-born Genetic Testing Market Competition by Company

1 Global Prenatal and New-born Genetic Testing Sales and Market Share by Company (2015-2020)

2.2 Global Prenatal and New-born Genetic Testing Revenue and Share by Company (2015-2020)

2.3 Global Prenatal and New-born Genetic Testing Price by Company (2015-2020)

2.4 Global Top Players Prenatal and New-born Genetic Testing Manufacturing Base Distribution, Sales Area, Product Types

2.5 Prenatal and New-born Genetic Testing Market Competitive Situation and Trends

2.5.1 Prenatal and New-born Genetic Testing Market Concentration Rate

2.5.2 Global Prenatal and New-born Genetic Testing Market Share of Top 5 and Top 10 Players

2.5.3 Mergers & Acquisitions, Expansion

3 Prenatal and New-born Genetic Testing Company Profiles and Sales Data

1 China Shipping Container Lines

3.1.1 Company Basic Information, Manufacturing Base and Competitors

3.1.2 Prenatal and New-born Genetic Testing Product Category, Application and Specification

3.1.3 China Shipping Container Lines Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin(2015-2020)

3.1.4 Main Business Overview

4 Prenatal and New-born Genetic Testing Market Status and Outlook by Regions

1 Global Market Status and Outlook by Regions

4.1.1 Global Prenatal and New-born Genetic Testing Market Size and CAGR by Regions

4.1.2 North America

4.1.3 Asia-Pacific

4.1.4 Europe

4.1.5 South America

4.1.6 Middle East and Africa

4.2 Global Prenatal and New-born Genetic Testing Sales and Revenue by Regions

4.2.1 Global Prenatal and New-born Genetic Testing Sales and Market Share by Regions (2015-2020)

4.2.2 Global Prenatal and New-born Genetic Testing Revenue and Market Share by Regions (2015-2020)

4.2.3 Global Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin (2015-2020)

4.3 North America Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin

4.3.1 United States

4.3.2 Canada

4.3.3 Mexico

4.4 Europe Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin

4.4.1 Germany

4.4.2 UK

4.4.3 France

4.4.4 Italy

4.4.5 Russia

4.4.6 Turkey

4.5 Asia-Pacific Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin

4.5.1 China

4.5.2 Japan

4.5.3 Korea

4.5.4 Southeast Asia

4.5.4.1 Indonesia

4.5.4.2 Thailand

4.5.4.3 Malaysia

4.5.4.4 Philippines

4.5.4.5 Vietnam

4.5.5 India

4.5.6 Australia

4.6 South America Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin

4.6.1 Brazil

4.7 Middle East and Africa Prenatal and New-born Genetic Testing Sales, Revenue, Price and Gross Margin

4.7.1 Egypt

4.7.2 GCC Countries

5 Prenatal and New-born Genetic Testing Application/End Users

1 Prenatal and New-born Genetic Testing Segment by Application

5.2 Global Prenatal and New-born Genetic Testing Product Segment by Application

5.2.1 Global Prenatal and New-born Genetic Testing Sales by Application

5.2.2 Global Prenatal and New-born Genetic Testing Sales and Market Share by Application (2015-2020)

6 Global Prenatal and New-born Genetic Testing Market Forecast

1 Global Prenatal and New-born Genetic Testing Sales, Revenue Forecast (2020-2026)

6.1.1 Global Prenatal and New-born Genetic Testing Sales and Growth Rate Forecast (2020-2026)

6.1.1 Global Prenatal and New-born Genetic Testing Revenue and Growth Rate Forecast (2020-2026)

6.2 Global Prenatal and New-born Genetic Testing Forecast by Regions

6.2.1 North America Prenatal and New-born Genetic Testing Sales and Revenue Forecast (2020-2026)

6.2.2 Europe Prenatal and New-born Genetic Testing Sales and Revenue Forecast (2020-2026)

6.2.3 Asia-Pacific Prenatal and New-born Genetic Testing Sales and Revenue Forecast (2020-2026)

6.2.3.1 China

6.2.3.2 Japan

6.2.3.3 Korea

6.2.3.4 Southeast Asia

6.2.3.5 India

6.2.3.6 Australia

6.2.4 South America Prenatal and New-born Genetic Testing Sales and Revenue Forecast (2020-2026)

6.2.5 Middle East and Africa Prenatal and New-born Genetic Testing Sales and Revenue Forecast (2020-2026)

6.2.5.1 Egypt

6.2.5.2 GCC Countries

6.3 Prenatal and New-born Genetic Testing Forecast by Type

6.3.1 Global Prenatal and New-born Genetic Testing Sales and Revenue Forecast by Type (2020-2026)

6.4 Prenatal and New-born Genetic Testing Forecast by Application

View original post here:
Prenatal and New-born Genetic Testing Market Projected to Discern Stable Expansion During 2020-2025 - The Daily Chronicle

Chicago, United States: The report on Global Prenatal and Newborn Genetic Testing Market provides the complete overview of the several key segments of the market. Report provides accurate calculation and qualitative analysis. Report gives the in depth analysis on various factors, for example market size, segmentations, competitive landscapes, geographical regions and end users. Regional analysis provides a systematic knowledge about the opportunities in business, market status & forecast, possibility of generating revenue, regional market by different end users as well as types and future forecast of upcoming years. The report entitled Global Prenatal and Newborn Genetic Testing Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 released by Report Hive Research comprises an assessment of the market which provides the real-time market scenario and its projections during 2020 to 2026 time-period [5 Years Forecast].

The report offers an understanding of the demographic changes that took place in recent years. The report presents an analysis of market size, share, growth, trends, statistical and comprehensive facts of the global Prenatal and Newborn Genetic Testing market. This research study presents informative information and in-depth evaluation of the market and its segments based totally on technology, geography, region, and applications.

>>>>The study encompasses profiles of major companies operating in the global Prenatal and Newborn Genetic Testing Market. Key players profiled in the report include: Roche Diagnostic, Elitech Group, Myriad Genetics, Biocartis, IntegraGen, Perkin Elmer, WaferGen Biosystem, Interpace Diagnostics, Quest Diagnostic, Bio-Rad, AutoGenomics, Abbott, Cepheid, EKF Diagnostics, Natera, Agilent Technologies, Illumina, Ariosa Diagnostics, Sequenom

Drivers And Risks:

The report covers the basic dynamics of the global Prenatal and Newborn Genetic Testing market. It scrutinizes several data and figures, and numerous volume trends. A number of potential growth factors, risks, restraints, challenges, market developments, opportunities, strengths, and weaknesses have been highlighted. Another factor affecting market growth has also been included in the report.

Regional Analysis:

The report comprises of regional development status, covering all the major regions of the world. This regional status shows the size (in terms of value and volume), and price data for the global Prenatal and Newborn Genetic Testing market. The development of the industry is assessed with information on the current status of the industry in various regions. Data type assessed concerning various regions includes capacity, production, market share, price, revenue, cost, gross, gross margin, growth rate, consumption, import, export, etc.

Regional coverage: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

The key questions answered in the report:

* What will be the market size and growth rate in the forecast year?

* What are the key factors driving the Global Prenatal and Newborn Genetic Testing Market?

* What are the risks and challenges in front of the market?

* Who are the key vendors in the Global Prenatal and Newborn Genetic Testing Market?

* What are the trending factors influencing the market shares?

* What are the key outcomes of Porters five forces model?

* Which are the global opportunities for expanding the Global Prenatal and Newborn Genetic Testing Market?

>>>>Get Full Customize report @ https://www.reporthive.com/request_customization/2516750

Table of Contents:

Reasons for Buying this Report:

* This report provides pin-point analysis for changing competitive dynamics

* It provides a forward looking perspective on different factors driving or restraining market growth

* It provides a six-year forecast assessed on the basis of how the market is predicted to grow

* It helps in understanding the key product segments and their future

* It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

* It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Get Free Sample Copy of this report: https://www.reporthive.com/request_sample/2516750

Why Go For Report Hive Research?

Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Get in Touch with Us :

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: : https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Originally posted here:
2020 Current Trends In Prenatal and Newborn Genetic Testing Market Share, Growth, Demand, Trends, Region Wise Analysis Of Top Players And Forecasts...

Developing knowledge about genetic systems for identification of chromosomal variations from the norm and fetus screening for effective IVF holds development prospects for this vertical over the estimate time frame. Early discovery of the chromosomal maladies, which holds potential for lowering the quantity of individuals experiencing intrinsic ailments, PGD can be performed for screening of a scope of restorative conditions, for example, Downs syndrome, inheritable illnesses and qualities of other physiological anomaly. Expanding tolerant awareness about PGD system and rising predominance of hereditary issue among newborn children has prompted the ascent sought after for PGD alongside IVF methodology. The mix of PGD and IVF has enhanced the rate of fruitful pregnancy because of decreased odds of passing the undesired hereditary material in the developing life. Thus decreases the quantity of offsprings conceived with acquired chromosomal variations from the norm. This can be credited to the expanded interest for Preimplantation genetic testing (PGT) administrations.

The scope of the report includes a detailed study of global and regional markets on Global Preimplantation Genetic Testing Market with the reasons given for variations in the growth of the industry in certain regions.

You Can Browse Full Report @: https://www.marketresearchengine.com/preimplantation-genetic-testing-market

The Global Preimplantation Genetic Testing Market is expected to exceed more than US$ 650 Million by 2024 at a CAGR of 10% in the given forecast period.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Cooper Surgical, Inc. (U.S.), and Beijing Genomics Institute (BGI) (China) Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Global Preimplantation Genetic Testing Market is segmented on the lines of its technology, product & service, procedure type, application, end user and regional. Based on technology segmentation it covers next generation sequencing (NGS), polymerase chain reaction (PCR), fluorescent in-situ hybridization (FISH), comparative genomic hybridization (CGH), single nucleotide polymorphism (SNP). Based on product & service segmentation it covers reagents & consumables, instruments, software & services. Based on procedure type segmentation it covers preimplantation genetic screening, preimplantation genetic diagnosis. Based on application segmentation it covers aneuploidy, structural chromosomal abnormalities, and single gene disorders, x-linked disorders, hla typing, gender identification. Based on end user segmentation it covers maternity centers & fertility clinics, hospitals, diagnostic labs, and service providers, research laboratories & academic institutes. The Global Preimplantation Genetic Testing Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

The Global Preimplantation Genetic Testing Market has been segmented as below:

The Global Preimplantation Genetic Testing Market is Segmented on the lines of Technology Analysis, Product & Service Analysis, Procedure Type Analysis, Application Analysis, End User Analysis and Regional Analysis. By Technology Analysis this market is segmented on the basis of Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-situ Hybridization (FISH), Comparative Genomic Hybridization (CGH) and Single Nucleotide Polymorphism (SNP). By Product & Service Analysis this market is segmented on the basis of Reagents & Consumables, Instruments and Software & Services. By Procedure Type Analysis this market is segmented on the basis of Preimplantation Genetic Screening and Preimplantation Genetic Diagnosis.

By Application Analysis this market is segmented on the basis of Aneuploidy, Structural Chromosomal Abnormalities its covers Translocations, Deletions, Duplications & Inversions. Single Gene Disorders, X-linked Disorders, HLA Typing and Gender Identification. By End User Analysis this market is segmented on the basis of Maternity Centers & Fertility Clinics sector, Hospitals, Diagnostic Labs, and Service Providers sector and Research Laboratories & Academic Institutes sector. By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

This report provides:

1) An overview of the global market for Global Preimplantation Genetic Testing Market and related technologies.2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.3) Identifications of new market opportunities and targeted promotional plans for Preimplantation Genetic Testing Market.4) Discussion of research and development, and the demand for new products and new applications.5) Comprehensive company profiles of major players in the industry.

The major driving factors of Global Preimplantation Genetic Testing Market are as follows:

The restraining factors of Global Preimplantation Genetic Testing Market are as follows:

Request Sample Report: https://www.marketresearchengine.com/preimplantation-genetic-testing-market

Table of Contents

1 Introduction

1.1 KEY TAKE AWAYS1.2 REPORT DESCRIPTION1.3 MARKETS COVERED1.4 STAKEHOLDERS1.5 RESEARCH METHODOLOGY1.5.1 MARKET SIZE1.5.2 MARKET SHARE1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Preimplantation Genetic Testing Market: Overview

6 Industry Insights

7 Preimplantation Genetic Diagnosis and Screening Market, By Procedure Type

8 Preimplantation Genetic Diagnosis and Screening Market, By Technology

9 Preimplantation Genetic Diagnosis and Screening Market, By Product and Service

10 Preimplantation Genetic Diagnosis and Screening Market, By Application

11 Preimplantation Genetic Diagnosis and Screening Market, By End User

12 Preimplantation Genetic Diagnosis and Screening Market, By Region

13 Preimplantation Genetic Testing Market: Competitive Landscape

14 Company Profiles

14.1 Top Product Manufacturers

14.1.1 Illumina, Inc.

14.1.2 Thermo Fisher Scientific Inc.

14.1.3 Agilent Technologies, Inc.

14.1.4 Perkinelmer, Inc.

14.1.5 Coopersurgical, Inc. (A Subsidiary of the Cooper Companies, Inc.)

14.1.6 ABBott Laboratories

14.1.7 Natera, Inc.

14.1.8 Rubicon Genomics (A Subsidiary of Takara Bio Usa Holdings, Inc.)

14.1.9 Oxford Gene Technology

14.1.10 Yikon Genomics

14.1.11 Scigene

14.2 Top Service Provider Companies

14.2.1 Beijing Genomics Institute

14.2.2 Good Start Genetics, Inc.

14.2.3 Invicta Genetics

14.2.4 Combimatrix Corporation

14.2.5 Genea Limited

14.2.6 Progenesis

Other Related Market Research Reports:

Plasma Fractionation Market to hit more than US$ 26 Billion By 2022

Planting Equipment Market is Expected to Grow US$ 20 Billion By 2022

Phosphate Esters Market Growth Factors Analysis, Product Overview and Share Forecasted to 2022

Media Contact

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com

See the article here:
Preimplantation Genetic Testing Market Industry Insights, Drivers, Top Trends, Global Analysis And Forecast to 2027 - The Daily Chronicle

Industry Insights:

The Global Direct-to-consumer Genetic Testing market is anticipated to reach XX USD billion with CAGR of xx% over the forecast period 2020 2026.

Market Growth Insight has presented an updated research report on The Global Direct-to-consumer Genetic Testing market which offers insights on key aspects and an overview of the fundamental verticals of the market. The Direct-to-consumer Genetic Testing report aims to educate buyers on the crucial impactful factors like drivers, challenges and opportunities for the market players, and risks. It comprises a thorough analysis of current Direct-to-consumer Genetic Testing market trends as well as future trends. It also throws light on various quantitative and qualitative assessments of the market. The Direct-to-consumer Genetic Testing research report covers every crucial aspect of the industry that impacts the existing market share, market size, profitability status, and more. A comprehensive evaluation on impacting factors the influence growth opportunities for Direct-to-consumer Genetic Testing market players and remuneration.

Download your FREE sample of the report here: https://www.marketgrowthinsight.com/sample/149941

The Major Manufacturers Covered in This Report:

Myriad Genetics, Inc., 23andMe, Inc., Invitae, Ambry Genetics, Laboratory Corporation of America, African Ancestry, MyHeritage, AncestrybyDNA, Counsyl, Inc., Pathway Genomics, DNA Services of America, Positive Bioscience Ltd., Quest Diagnostics, Sonora Quest Laboratories, Gene by Gene, Mapmygenome

COVID-19 Outlook:

Researchers have extensively study on the impact of the pandemic on different segments of the Direct-to-consumer Genetic Testing market. They have precisely mentioned the risks associated with the speedy spread of infection in different regions and offered insights on the crucial areas. This will help the businesses to plan their strategies for better Direct-to-consumer Genetic Testing market position post-pandemic. The report also covers qualitative details about when the industry could return on track and potential measures adopted by the Direct-to-consumer Genetic Testing market vendors to tackle the existing situation.

The report further elucidates on the restraining factors in the Direct-to-consumer Genetic Testing market for business owners, strategists, and stakeholders to carefully execute their strategies and achieve their goals. In addition, the Direct-to-consumer Genetic Testing market is segmented on the basis of product, technology, and end-user. These Direct-to-consumer Genetic Testing report segments are thoroughly studied to offer key information like opportunities for business owners, planners, and marketing personnel. It helps them to manage their activities and execute decisive planning to earn more profits. Direct-to-consumer Genetic Testing Report offers insights on each segment and sub-segment for assisting manufacturers to identify key opportunities and expand their business.

Geographically, the detailed analysis of consumption, revenue, Direct-to-consumer Genetic Testing market share and growth rate, historic and forecast (2015-2026) of the following regions are covered:

North America (United States, Canada, Mexico)Europe (Germany, UK, France, Italy, Spain, Russia, Others)Asia-Pacific (China, Australia,South Korea,Japan, India, Southeast Asia, Others)Middle East and Africa (UAE, Saudi Arabia, Egypt, South Africa, Nigeria, Others)South America (Brazil, Argentina, Columbia, Chile, Others)

Request a discount on standard prices of this premium research @ https://www.marketgrowthinsight.com/discount/149941

In addition, the report focuses on the key technological improvements in the products and key growth strategies adopted by Direct-to-consumer Genetic Testing market players to expand their business vertically and horizontally. Company information, recent strategies, highly demanding products by manufacturers, and manufacturing units including other essential details are mentioned in the Direct-to-consumer Genetic Testing study. Research and development activities and new product development and other trending factors are highlighted in the Direct-to-consumer Genetic Testing report to offer deeper insights to the buyers. The Direct-to-consumer Genetic Testing report is also beneficial to investors for their investment planning and company information.

Study Objective of the Direct-to-consumer Genetic Testing market includes:

Table and Figures Covered in This Report:

Inquire more or share questions if any before the purchase on this report @ https://www.marketgrowthinsight.com/inquiry/149941

About Market Growth Insight

We are striving to provide the best customer friendly services and appropriate business information to accomplish your ideas. The skilled and experienced professionals at Market Growth Insight are our strength and the position we have earned in the industry. This is what makes us to offer our clients to excel and enable competitive prices while retaining the best services. We are incorporated with a vision to provide the complete solution required for successful business execution. Our only motto is to resolve customer fulfillment completely. We provide the quality and customized research reports from the best publishers in the world.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:https://www.marketgrowthinsight.com

Read the original here:
Direct-to-consumer Genetic Testing Market is Growing at a High CAGR by 2024 According to a New Research Report by Myriad Genetics, Inc., 23andMe,...

The Direct-to-consumer Genetic Testing Market research report provides key statistics of the market status in terms of Direct-to-consumer Genetic Testing market size estimates and forecasts, growth rate. This report also covers key players of the market identified through their market share, product offerings. Further, the Direct-to-consumer Genetic Testing market research report strategical insights based on assessment of recent developments, strategy analysis of the players. It also covers drivers, opportunity and challenges prevailing in the industry. The report covers segmental analyses for across the key region North America, Europe, Asia Pacific, Middle East & Africa and South America.

Get a sample copy of the report at https://www.industryresearch.biz/enquiry/request-sample/16203015

The Global Direct-to-consumer Genetic Testing market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Direct-to-consumer Genetic Testing market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analysed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Final Report will add the analysis of the impact of COVID-19 on this industry.

In Chapter 2.4 of the report, we share our perspectives for the impact of COVID-19 from the long and short term.In chapter 3.4, we provide the influence of the crisis on the industry chain, especially for marketing channels.In chapters 8-13, we update the timely industry economic revitalization plan of the country-wise government.

To Understand How Covid-19 Impact Is Covered in This Report https://www.industryresearch.biz/enquiry/request-covid19/16203015

The objective of this report:

Global Direct-to-consumer Genetic Testing market competition by TOP MANUFACTURERS, with production, price, revenue (value) and each manufacturer including:

Global Direct-to-consumer Genetic Testing Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and instrumentation and downstream demand analysis is additionally dispensed. The Global Direct-to-consumer Genetic Testing market development trends and marketing channels are analyzed. Finally, the feasibility of latest investment projects is assessed and overall analysis conclusions offered.

Enquire before purchasing this report https://www.industryresearch.biz/enquiry/pre-order-enquiry/16203015

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 8-13:

Get a sample copy of the Direct-to-consumer Genetic Testing Market Report 2020

Some of the key questions answered in this report:

Years considered for this report:

Purchase this report (Price 3500 USD for a single-user license) https://www.industryresearch.biz/purchase/16203015

With tables and figures helping analyse worldwide Global Direct-to-consumer Genetic Testing market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Key Points from TOC:

1 Market Overview1.1 Product Definition and Market Characteristics1.2 Global Direct-to-consumer Genetic Testing Market Size1.3 Market Segmentation1.4 Global Macroeconomic Analysis1.5 SWOT Analysis

2. Market Dynamics2.1 Market Drivers2.2 Market Constraints and Challenges2.3 Emerging Market Trends2.4 Impact of COVID-192.4.1 Short-term Impact2.4.2 Long-term Impact

3 Associated Industry Assessment3.1 Supply Chain Analysis3.2 Industry Active Participants3.2.1 Suppliers of Raw Materials3.2.2 Key Distributors/Retailers3.3 Alternative Analysis3.4 The Impact of Covid-19 From the Perspective of Industry Chain

4 Market Competitive Landscape4.1 Industry Leading Players4.2 Industry News4.2.1 Key Product Launch News4.2.2 M&A and Expansion Plans

5 Analysis of Leading Companies5.1 Company 15.1.1 Company 1 Company Profile5.1.2 Company 1 Business Overview5.1.3 Company 1 Direct-to-consumer Genetic Testing Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.1.4 Company 1 Direct-to-consumer Genetic Testing Products Introduction

5.2 Company 25.2.1 Company 2 Company Profile5.2.2 Company 2 Business Overview5.2.3 Company 2 Direct-to-consumer Genetic Testing Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.2.4 Company 2 Direct-to-consumer Genetic Testing Products Introduction

5.3 Company 35.3.1 Company 3 Company Profile5.3.2 Company 3 Business Overview5.3.3 Company 3 Direct-to-consumer Genetic Testing Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.3.4 Company 3 Direct-to-consumer Genetic Testing Products Introduction

5.4 Company 45.4.1 Company 4 Company Profile5.4.2 Company 4 Business Overview5.4.3 Company 4 Direct-to-consumer Genetic Testing Sales, Revenue, Average Selling Price and Gross Margin (2015-2020)5.4.4 Company 4 Direct-to-consumer Genetic Testing Products Introduction

6 Market Analysis and Forecast, By Product Types6.1 Global Direct-to-consumer Genetic Testing Sales, Revenue and Market Share by Types (2015-2020)6.2 Global Direct-to-consumer Genetic Testing Market Forecast by Types (2020-2025)6.3 Global Direct-to-consumer Genetic Testing Sales, Price and Growth Rate by Types (2015-2020)6.4 Global Direct-to-consumer Genetic Testing Market Revenue and Sales Forecast, by Types (2020-2025)

7 Market Analysis and Forecast, By Applications7.1 Global Direct-to-consumer Genetic Testing Sales, Revenue and Market Share by Applications (2015-2020)7.2 Global Direct-to-consumer Genetic Testing Market Forecast by Applications (2020-2025)7.3 Global Revenue, Sales and Growth Rate by Applications (2015-2020)7.4 Global Direct-to-consumer Genetic Testing Market Revenue and Sales Forecast, by Applications (2020-2025)

8 Market Analysis and Forecast, By Regions8.1 Global Direct-to-consumer Genetic Testing Sales by Regions (2015-2020)8.2 Global Direct-to-consumer Genetic Testing Market Revenue by Regions (2015-2020)8.3 Global Direct-to-consumer Genetic Testing Market Forecast by Regions (2020-2025)Continued.

Detailed TOC of Global Direct-to-consumer Genetic Testing Market @ https://www.industryresearch.biz/TOC/16203015

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Sodium Fluorosilicate Market Size 2020 By Trends Evaluation, Global Growth, Consumer-Demand, Consumption, Strategies, MarketDynamics (Opportunities, Risk, DrivingForce) and Forecast till 2029

Global Underground Distribution Switchgear Market Size & Share, 2020 Movements by Latest Trend Analysis, Progression Status, Revenue Expectation to 2026, Research Report by Industry Research Biz

Lifeboat Market 2020 Analysis By Worldwide Industry Trends, Size, Share, Gross Margin, Future Demand, Analysis and Forecast by Top Leading Players Update till 2029

Wetsuits Market Size & Forecast 2020-2024 By Global Industry Trends, Development History, Regional Overview, Share Estimation, Revenue, and Business Prospect, Says Industry Research Biz

Global Class 1 Ceramic Capacitor Market Size and Share 2020 Report by Sales Revenue, Future Demands, Growth Factors, Emerging Trends, Competitive Landscape and Forecast to 2026

Solder Market 2020-2029 Analysis By Global Industry Trends, Future Growth, Regional Overview, Size, Share Estimation, Revenue, and Outlook, Says Industry Research Biz

Global Railway Air Spring Market Size 2020 Industry Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers and 2026 Forecast Research Report

Read this article:
Global Direct-to-consumer Genetic Testing Market Size 2020 Industry Overview, Shares, Growing Demand, Explosive Factors of Revenue, Types,...

In this report, the global Predictive Genetic Testing market is valued at USD XX million in 2019 and is projected to reach USD XX million by the end of 2025, growing at a CAGR of XX% during the period 2019 to 2025.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Predictive Genetic Testing market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Predictive Genetic Testing market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Predictive Genetic Testing market to assist our clients arrive at beneficial business decisions.

The Predictive Genetic Testing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the Predictive Genetic Testing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/31204

Resourceful insights enclosed in the report:

The major players profiled in this Predictive Genetic Testing market report include:

key players in the predictive genetic testing market. The significant competitive strength of the existing players in the evolving landscape of the global predictive genetic testing market is anticipated to offer new prospect in widening the application of the predictive genetic testing, substantially driving predictive genetic testing market growth. The key manufacturers of the predictive genetic testing are greatly concentrated on the technical edification of the end users to improve consumer outcomes. Furthermore, the adoptions of advanced predictive genetic testing services is expected to create lucrative growth opportunities for the service and third-party market competitors. Growing inclination toward trend in predict is prevention is estimated to offer growth opportunity for Predictive genetic testing market. Selection of treatment regimen with Predictive genetic testing is projected to aid capturing higher share in Predictive genetic testing market.

Geographically, global Predictive genetic testing market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia Oceania and Middle East & Africa. North America is prominent region in Predictive genetic testing Market. Advancement in genetic care facilities, higher adoption to lifestyle changes, increase awareness about genetic disease, increase in preventative care and favorable government policies have improved the regulatory scenario for predictive genetic testing devices in north America. Additionally in Asia pacific region considerably higher market growth rate is expected due to constantly rising population and higher incidence of genetic abnormality. Relatively affecting the Predictive genetic testing market.

Some of the major key players competing in the global Predictive genetic testing Market are Myriad Genetics, Inc., Abbott Laboratories, Illumina, Inc., Genesis GeneticsThermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc., , Agilent Technologies, F. Hoffmann-La Roche Ltd., Counsyl, Inc., ARUP Laboratories. BGI among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/31204

The market report addresses the following queries related to the Predictive Genetic Testing market:

The study objectives of Predictive Genetic Testing Market Report are:

To analyze and research the Predictive Genetic Testing market status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.

To present the Predictive Genetic Testing manufacturers, presenting the sales, revenue, market share, and recent development for key players.

To split the breakdown data by regions, type, companies and applications

To analyze the global and key regions Predictive Genetic Testing market potential and advantage, opportunity and challenge, restraints and risks.

To identify significant trends, drivers, influence factors in global and regions

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the Predictive Genetic Testing market.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/31204

Read more:
Global Region Likely to Dominate the Predictive Genetic Testing Market Over the Forecast Period 2019 2029 - The Daily Chronicle

A new research report published by Fior Markets with the titleCannabis Testing Market by Product & Software (Analytical Instruments, Consumables, Software), Testing Procedures (Residual Solvent Screening, Terpene Profiling, Potency Testing, Genetic Testing, Pesticide Screening, Heavy Metal Testing, Microbial Analysis), End-User (Laboratories, Cannabis Cultivators, Research Institutes, Drug Manufacturers & Dispensaries), Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2020 to 2027.

Theglobal cannabis testing marketis expected to grow from USD 1.71 billion in 2019 to USD 4.87 billion by 2027, at a CAGR of 14% during the forecast period 2020-2027. North America dominated the market in the year 2019. This growth was due to the growing legalization pertaining to the use of cannabis across various U.S. states, increasing cultivators of marijuana, and the rising number of testing laboratories. The growing demand for cannabis for personal use will further propel the market growth. The Chile cannabis testing market is anticipated to grow due to the growing awareness of the medical use of cannabis and the increase in cannabis use for medical purposes. The Germany market is expected to witness significant growth due to increased approval of production licenses and new medical cannabis legislation.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/418923/request-sample

Some of the notable players in the market are CannaSafe Analytics, Steep Hill, Anandia Labs, Eirlab, Phytovista Laboratories, CW Analytical Laboratories, Pure Analytics, Anresco, EVIO, SC Labs, and Digipath. In January 2019, Hemp Inc. and Digipath Inc. has an agreement to provide on-site potency testing laboratories for three hemp production sites in Arizona and Oregon that are owned by Hemp Inc. This collaboration enabled Digipath to expand its market share and strengthen its position in the international as well as domestic cannabis testing industry.

The product & software segment includes analytical instruments, consumables, and software. The analytical instruments segment is further segmented into chromatography instruments, spectroscopy instruments, and other analytical instruments. The chromatography instruments are further classified into liquid chromatography, gas chromatography, and other chromatography instruments. The spectroscopy instruments segment is further classified into mass spectrometry, atomic spectroscopy, and atomic spectroscopy. The chromatography instruments are further classified into liquid chromatography, gas chromatography, and other chromatography instruments. The spectroscopy instrument segment is anticipated to witness significant growth due to the increasing legalization of cannabis testing and its derivative for adults recreational and medical use. The testing procedure segment includes residual solvent screening, terpene profiling, potency testing, genetic testing, pesticide screening, heavy metal testing, and microbial analysis. The potency testing segment holds the largest market share, owing to the increasing applications of cannabinoids for medical purposes. It is also essential for the precise labeling of medical purposes. On the basis of end-user, the market is segmented into laboratories, cannabis cultivators, research institutes, and drug manufacturers & dispensaries. Laboratories segment dominated the market, due to the increasing legalization of cannabis for medical as well as recreational use, and rising demand for cannabis testing software in labs.

The factors influencing the market are growing number of medical applications of cannabis, rising investment by various research institutes, increasing focus to meet the needs of hemp and cannabis cultivator, and legalization of medical cannabis associated with a rising number of cannabis analysis laboratories. The factors restraining the market are high cost of laboratory equipment and lack of uniformity in quality standards.

ACCESS FULL REPORT:https://www.fiormarkets.com/report/cannabis-testing-market-by-product-software-analytical-418923.html

About the report:The globalcannabis testing market is analyzed on the basis of value (USD Billion), volume (K Units), export (K Units), and import (K Units). All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

Customization of the Report:The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

Contact UsMark StonePhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Read the rest here:
Global Cannabis Testing Market is projected to grow at a CAGR of 14% during the forecast period 2020 - PharmiWeb.com

Newark, NJ,, Sept. 29, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal esoteric testing market is expected to grow from USD 22.82 billion in 2019 and to reach USD 56.51 billion by 2027, growing at a CAGR of 12% during the forecast period 2020-2027.

The global esoteric testing market is witnessing significant growth from recent years. This growth is attributed to the rising prevalence of chronic and infectious diseases like diabetes, cancer, and various others. Technological advancements such as standardization of advanced instrumentation, antidote automation technology, and analytical systems will propel the market growth. Furthermore, growing awareness regarding early disease diagnosis and its treatment, increasing incidence of complex and unique diseases, and rapidly improving healthcare sector will influence the market growth.

An analysis of a unique molecule or substances that are not performed in the routine clinical laboratory is known as esoteric testing. Esoteric testing requires sophisticated materials and instruments and specialized personnel to perform and analyze results. The doctors require esoteric testing for accruing large amounts of data outside routine tests in labs and overall analysis, prediction and monitoring of the healing regimen. These tests are typically related to medical fields like genetics, endocrinology, microbiology, oncology, molecular diagnostics, toxicology, and serology.

The global esoteric testing market is expected to witness significant growth, owing to the growing awareness of personalized medicines, rising geriatric population, increasing funding and research grants for the development of innovative esoteric tests, and rising demand for early disease detection using specialized diagnostic tests. Unfavourable reimbursement scenario, lack of sufficient expertise, and an insufficient number of esoteric testing modules will restrain the market growth. An increase in private and public funding to support research activities will provide market growth opportunities. However, changing regulatory framework will challenge the market.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418896/request-sample

The key players operating in global esoteric testing market are Mayo Medical Laboratories, Laboratory Corporation of America, Fulgent Genetics, Quest Diagnostics, Genomic Health, OPKO Health, Nordic Laboratories, Arup Laboratories, American Esoteric Laboratories (AEL), ACM Global Laboratories, Myriad Genetics, BioMONTR, Invitae, and Miraca Holdings. To gain a significant market share in the global esoteric testing market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint venture, collaborations, and partnership. Genomic Health and BioMONTR are some of the leading players in esoteric testing.

Infectious disease testing segment dominated the market and held the largest share of 23.67% in the year 2019On the basis of type, the global esoteric testing market is segmented into endocrinology, infectious disease, immunology, toxicology, neurology, and genetic testing. Infectious disease testing segment dominated the market and held the largest share of 23.67% in the year 2019. This growth is attributed to the high prevalence of infectious diseases and increasing demand for advanced molecular tests, and the availability of immunology laboratory services.

CLIA technology segment dominated the market and held the largest market share of 36.9% in the year 2019On the basis of technology, the global esoteric testing market is segmented into mass spectrometry, ELISA, CLIA, and PCR. CLIA technology segment dominated the market and held the largest market share of 36.9% in the year 2019. This growth is attributed to the advantages of CLIA over other testing methods, low detection limits, superior sensitivity and accuracy delivered, and high adoption of CLIA in esoteric testing. ELISA esoteric technology is anticipated to witness significant growth due to the high throughput screening performed in laboratories, new development in biomarkers, and drug discovery programs.

Browse full report with TOC athttps://www.fiormarkets.com/report/esoteric-testing-market-by-type-endocrinology-infectious-disease-418896.html

Independent lab segment dominated the market and held the largest share of 54.64% in the year 2019On the basis of lab type, the global esoteric testing market is segmented into hospital laboratories and independent labs. Independent lab segment dominated the market and held the largest share of 54.64% in the year 2019. This growth is attributed to ongoing automation and digitalization of diagnostic laboratories, and significant reimbursement coverage for clinical tests performed at independent laboratories.

Regional Segment of Esoteric Testing Market

On the basis of geography, the global esoteric testing market is classified into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America held the major share of 29.1% in the year 2019. This growth was attributed to an increasing number of research activities in healthcare, increasing patient population suffering from chronic disease, growing investment in healthcare, and quick adoption of sophisticated instruments. Canada is anticipated to witness significant growth, owing to the increasing demand for cost-effective methods of diagnosis. The South America region market is expected to grow, owing to the increasing demand for treatment options for chronic diseases and technologically advanced devices for diagnosis. The Asia-Pacific region is projected to grow due to an increasing focus on early diagnosis and treatment for rare diseases and the increasing burden of chronic diseases. The Middle East and Africa market is witnessing a steady rise due to an increase in the number of healthcare facilities and awareness about esoteric testing.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418896About the report:The global esoteric testing market is analysed on the basis of value (USD billion). All the segments have been analysed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insights of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, and competitors position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418896&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.marketquest.biz

Related ReportsGlobal Pedicle Screw System Market - https://www.fiormarkets.com/report/global-pedicle-screw-system-market-by-product-polyaxial-375967.htmlGlobal Pharmaceutical Contract Manufacturing Market - https://www.fiormarkets.com/report/global-pharmaceutical-contract-manufacturing-market-by-product-api-375968.htmlGlobal Rapid Microbiology Testing Market - https://www.fiormarkets.com/report/global-rapid-microbiology-testing-market-by-product-instruments-375969.htmlGlobal Spirometer Market - https://www.fiormarkets.com/report/global-spirometer-market-by-product-consumables-accessories-375970.html

Visit link:
Global Esoteric Testing Market Is Expected to Reach USD 56.51 billion by 2027 : Fior Markets - GlobeNewswire

Direct-to-consumer Genetic Testing Marketsize is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 15.0% in the forecast period of 2020 to 2025 and will expected to reach USD 2277.9 million by 2025, from USD 1301.3 million in 2019.

Direct-to-consumer Genetic Testing market research Report is an inestimable supply of perceptive information for business strategists. This Direct-to-consumer Genetic Testing Market study provides comprehensive data which enlarge the understanding, scope and application of this report.

A specific study of competitive landscape of the global Direct-to-consumer Genetic Testing Market has granted, providing insights into the corporate profiles, financial standing, recent developments, mergers and acquisitions, and therefore the SWOT analysis. This analysis report will provides a transparent program to readers concern regarding the overall market situation to further choose on this market projects.

The Direct-to-consumer Genetic Testing Market report profiles the successive companies, which includes: 23andMe, DNA Diagnostics Center, Myriad Genetics, MyHeritage, Gene By Gene, LabCorp, IntelliGenetics

Get Sample Copy of this Report @https://www.reportsintellect.com/sample-request/934984

This report studies the global Direct-to-consumer Genetic Testing Market status and forecast, categorizes the global Direct-to-consumer Genetic Testing Market size (value & volume), revenue (Million USD), product price by manufacturers, type, application, and region. Direct-to-consumer Genetic Testing Market Report by Material, Application and Geography with Global Forecast to 2025 is an connoisseur and far-reaching research provide details associated with worlds major provincial economic situations, Concentrating on the principle districts (North America, South America Europe, and Asia-Pacific) and the crucial nations (United States, Germany, United Kingdom, Japan, South Korea, and China).

Reports Intellect analysts are currently working analyzing and integrating their insights on the effect of COVID-19 across diverse industry verticals. These insights are quite promising for various businesses and industries to cope up with this unprecedented downturn and take effective strategic decisions to thrive and proliferate in the ever competitive business ecosystem.

By Types:Diagnostic Screening, Prenatal, Newborn Screening, and Pre-Implantation Diagnosis

By Applications:Online, Offline

Market Segment by Regions, regional analysis coversNorth AmericaEuropeAsia-PacificSouth AmericaMiddle East and Africa

Table of Contents

Global Direct-to-consumer Genetic Testing Market Size, Status and Forecast 20251 Market Overview2 Manufacturers Profiles3 Global Direct-to-consumer Genetic Testing Sales, Revenue, Market Share andCompetitionby Manufacturer4 Global Direct-to-consumer Genetic Testing Market Analysis by Various Regions5 North America Direct-to-consumer Genetic Testing by Countries6 Europe Direct-to-consumer Genetic Testing by Countries7 Asia-Pacific Direct-to-consumer Genetic Testing by Countries8 South America Direct-to-consumer Genetic Testing by Countries9 Middle East and Africas Direct-to-consumer Genetic Testing by Countries10 Global Direct-to-consumer Genetic Testing Market Segment by Types11 Global Direct-to-consumer Genetic Testing Market Segment by Applications12 Direct-to-consumer Genetic Testing Market Forecast13 Sales Channel, Distributors, Traders and Dealers14 Research Findings and Conclusion15 Appendix

Get a Good Amount of Discount on this reports @https://www.reportsintellect.com/discount-request/934984

Overview of the chapters analysing the global Direct-to-consumer Genetic Testing Market in detail:

Reasons why you should buy this report

About Us:-Reports Intellect is your one-stop solution for everythingassociated with market researchand market intelligence.

Our exhausting team works hard to fetchthe best authentic research reports backed with impeccable data figures that guarantee outstanding resultsanytimefor you.

So, whetheritsthe most recentreport from the researchers or a custom requirement, our team is hereto helpyou within absolute bestmanner.

Contact Us:

Sales@reportsintellect.comPH + 1-706-996-2486US Address:225 Peachtree Street NE,Suite 400,Atlanta, GA 30303

Go here to read the rest:
Direct-to-consumer Genetic Testing Market will Generate Record Revenue by 2025 with top key players like 23andMe, DNA Diagnostics Center, Myriad...

STEAMBOAT SPRINGS You can hear the love in Mariah Gillaspies voice as she talks about her daughters Emma and Abby, who suffer from a rare genetic disease that causes seizures and development issues.

Emma, shes our oldest, and shell be 4 in October, Mariah said. Shes our calm, sweet little child. She has these little coos that sound like a dove. She really enjoys music, and she loves being around other kiddos her age.

Abby is our younger daughter, and shell be 2 in October, and she is our feisty little thing, Mariah continued. So, she lets you know when shes happy; she lets you know when shes not happy.

There is no question the two girls, the only two people in the world believed to have this disease, are surrounded by the love they get from Mariah and their dad Mark.

Mark grew up in Steamboat Springs and graduated from high school here in 2001. The couple now live in Centennial, but Marks parents, Jeanne and Joe Gillaspie, still live in Steamboat as does Marks older brother.

Four years ago, Mark and Mariah were overwhelmed with joy as they welcomed their first child Emma to the world, but when she was three months old, the couple started to notice she was having some strange movements, and when she started having episodes where she would hold her breath until she would turn pale, the couple took her to the doctor.

The doctor initially thought it was reflux, but when Emma stopped breathing in the doctors office, she was rushed to Childrens Hospital of Colorado for more evaluation and tests.

Throughout all this, I was convinced everything was going to be OK, Mariah said. It never crossed my mind that something was seriously wrong, and I had never considered that these were seizures.

Eventually, Emma was diagnosed with infantile spasms, which Mariah said didnt look serious on the outside but were damaging Emmas brain and impacting her development from the inside. Emma started treatment immediately, and the family was encouraged with the results. But then there was a relapse and a new medication, and then another relapse and another new medication.

Mariah said each new medicine came with a longer list of side effects, and Emmas immune system suffered. She had a bout with pneumonia that left her in the hospital for two months.

Through it all, the Gillaspies continued to search for answers.

We did a whole slew of genetic testing, and it came back inconclusive, Mariah said. They found absolutely nothing that could be the cause of her disease, and they told us this is probably some completely random condition that was caused by something that happened in utero.

They also told the Gillaspies that Emmas condition was rare, and there was less than a 3% chance of it happening again. So after extensive genetic testing, they decided to have a second child.

When Abby arrived two years later, they were thrilled, but at about six weeks, they noticed their youngest daughter was displaying the same movements that Emma had shown prior to her diagnosis. So it was back to the doctors, and it was confirmed through genetic testing that Abby and Emma shared the same mutated gene THAP12.

After discovering their daughters were suffering from the same condition, the family embarked on a grassroots effort to drive research about the rare genetic disease, which led to the creation of a foundation, Lightning and Love, a name that was chosen because the family believes lightning struck their family twice in the form of two daughters with the same rare disease.

The doctors would say, Im sorry, theres nothing we can do. We have to wait for science to catch up,' Mariah said. Every doctor that weve encountered has really been amazing and done their very best for us. Its just unfortunate science hasnt caught up to the girls, yet. Thats kind of, whereas parents, were passionate enough to move science along a little faster.

The nonprofit organization is supported by a GoFundMePage, and tax-deductible donations can be made through the Lightning and Love website.

The latest research funded by the foundation involved genetically engineering a zebrafish model to see if it showed symptoms of disease, specifically seizures. The zebrafish did have seizures, which Mariah said was a major breakthrough toward the ultimate goal of finding a gene replacement cure for her daughters.

But the journey for Mark and Mariah has proven to be more than just research and discovery.

What were realizing is the more we talk about it, and the more we do to get our story out there, the more were realizing that theres a lot of other parents that are going through tough times with their kids, too, Mark said. In an odd twist, or an ironic twist, this tough hand that weve been dealt has actually been a very positive light to a lot of other people out there. For me, that is just as important as the research.

The familys story was recently featured on the podcast, Go Shout Love.

The couples positive message is guiding them along the road they hope will lead to a better life for their family. But in the meantime, Mark and Mariah will continue to put smiles ontheir daughters faces the same way most other parents do by offering their love, support and opportunities to find happiness.

For Emma, that means being tossed into the air and caught by her daddy, and for Abby, it is time in her sensory room and being around her dad and her family.

Emma loves very big movements. Shes not mobile, and she cant walk, so when we kind of throw her around in the air or fly her around the room, she absolutely loves it, Mariah said. Abby loves her daddy. She gives big old smiles when he walks into the room.

To reach John F. Russell, call 970-871-4209, email jrussell@SteamboatPilot.com or follow him on Twitter @Framp1966.

Read the rest here:
Family seeks answers, finds hope after daughters diagnosed with rare genetic condition - Steamboat Pilot and Today

Newark, NJ, Sept. 30, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal hemoglobinopathies market is expected to grow from USD 6.35 billion in 2019 to USD 13.72 billion by 2027, at a CAGR of 10.1% during the forecast period 2020-2027.

Some of the key factors that are driving the global hemoglobinopathies market are rising cases of hemoglobinopathies, increasing government initiatives for spreading awareness regarding hemoglobin variant diseases, growing R&D activities for developing novel therapeutics, rising cases of hemoglobin disorders such as thalassemia, Sickle Cell Disease (SCD), Hb C, & Hb E, unmet treatment needs, absence of a permanent cure, improvement in healthcare infrastructure, and rising cases of blood cancer.

Hemoglobinopathy is a genetic disorder that can result in defective globin chains. They are single-gene inherited disorders of which SCD is the most common. There is a high occurrence of Hemoglobinopathies in the Mediterranean, Southeast Asia, and Africa. If left untreated, hemoglobinopathy can lead to organ dysfunction, anemia, and even death in critical cases. Thalassemias, sickle cell anemia, hemoglobin S-C and hemoglobin C are some of the common hemoglobinopathies diseases. Typically, they are found by tests such as red blood cell count, hemoglobin isoelectric focusing, high performance liquid chromatography, etc.

With the outbreak of a global pandemic, many have faced salary cuts and job losses. Covid-19 has become a threat to the entire world's economy and has negatively impacted all kinds of markets, including the hemoglobinopathies market. With less disposable income and broken supply chains for equipment & tools, the market's growth is expected to slow down. Other factors that restrict market growth are diagnostic alternatives to hemoglobinopathies and an insufficient number of proper diagnostics test kits.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/418901/request-sample

Key players operating in the global hemoglobinopathies market include Alnylam Pharmaceuticals, Gamida Cell, Sanofi, Global Blood Therapeutics, Sangamo Therapeutics Inc., Bluebird Bio Inc., Prolong Pharmaceuticals, Celgene Corporation, and Emmaus Life Sciences Inc., among others. To gain a significant market share in the global hemoglobinopathies market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships. Global Blood Therapeutics and Bluebird Bio Inc. are some of the biggest players in the global hemoglobinopathies market.

Sickle cell disease dominated the market and held the largest market share of 38.4% in the year 2019

On the basis of type, the market has been segmented into sickle cell disease, thalassemia, and others. Sickle cell disease dominated the market and held the largest market share of 38.4% in the year 2019. The large share of this segment was attributed to the increasing patient awareness about disorders and improvements in diagnosis & treatment. This segment is also expected to expand at a significant CAGR during the forecast period.

Red blood cell (RBC) count test segment dominated the market and valued at USD 1.2 billion in the year 2019

Based on diagnosis, the global market has been divided into genetic testing, red blood cell (RBC) count test, hemoglobin isoelectric (Hb IEF) focusing, hemoglobin by high performance liquid chromatography (HPLC) test, hemoglobin solubility test, and hemoglobin electrophoresis (Hb ELP) test). Red blood cell (RBC) count test segment dominated the market and valued at USD 1.2 billion in the year 2019. The red blood cell (RBC) count test is the most commonly used first-line screening method.

Blood transfusion dominated the market and held the largest market share of 29.3% in the year 2019

Based on therapy, the hemoglobinopathies market has been segmented into blood transfusion, bone marrow transplant, iron chelation therapy, and others. Blood transfusion dominated the market and held the largest market share of 29.3% in the year 2019. The large share of this segment is attributed to factors like its high acceptance, high success rate, and rising government initiatives for increasing blood donations.

Browse full report with TOC athttps://www.fiormarkets.com/report/hemoglobinopathies-market-by-type-sickle-cell-disease-thalassemia-418901.html

Regional Segment Analysis of the Hemoglobinopathies Market

On the basis of geography, the global hemoglobinopathies market has been classified into North America, Europe, South America, Asia Pacific, and Middle East and Africa. The North America region accounted for the major market share of 45.25% in the year 2019 and is anticipated to grow throughout the projected period. The large share of this segment is attributed to key factors such as increasing R&D investments by major players, good reimbursement scenario, presence of advanced healthcare infrastructure, increasing prevalence of blood disorders, supportive government programs, and rising awareness among patients & healthcare professionals regarding hemoglobinopathies-related genetic testing. On the other hand, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period 2020-2027. This growth is due to factors like the introduction of low-cost, indigenously-manufactured diagnostic kits for sickle cell disease & thalassemia, rising patient awareness levels, unmet clinical needs, and developing healthcare infrastructure.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/418901

About the report:

The global hemoglobinopathies market is analyzed on the basis of value (USD Billion). All the segments have been analyzed on a global, regional, and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=418901&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Know More Market Research Reports and Industry Analysis, Visit our Associate Website: https://marketandresearch.biz

Related Reports

Disposable Medical Protective Masks Market - https://www.fiormarkets.com/report/global-disposable-medical-protective-masks-market-by-type-418624.htmlViscosupplementation Market - https://www.fiormarkets.com/report/viscosupplementation-market-by-product-type-single-injection-three-418859.htmlImmune Health Supplements Market - https://www.fiormarkets.com/report/immune-health-supplements-market-by-ingredient-type-vitamins-418776.htmlDigital Prescription Technology Market - https://www.fiormarkets.com/report/digital-prescription-technology-market-by-product-solutions-integrated-418775.html

Originally posted here:
Global Hemoglobinopathies Market Is Expected to Reach USD 13.72 Billion by 2027 : Fior Markets - GlobeNewswire

Fort Collins, Colorado The Preimplantation Genetic Testing Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The Preimplantation Genetic Testing Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the Preimplantation Genetic Testing Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global Preimplantation Genetic Testing Market was valued at 401.49 million in 2019 and is projected to reach USD796.89 million by 2027, growing at a CAGR of 9.65% from 2020 to 2027.

Industry Preimplantation Genetic Testing Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=32828

The report provides comprehensive data on the Preimplantation Genetic Testing market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The Preimplantation Genetic Testing Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the Preimplantation Genetic Testing market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

1.Preimplantation Genetic Testing Market, By Technology:

Next-Generation Sequencing Polymerase Chain Reaction Fluorescence in Situ Hybridization Comparative Genomic Hybridization Single-Nucleotide Polymorphism

2.Preimplantation Genetic Testing Market, By Procedure Type:

Preimplantation Genetic Screening Preimplantation Genetic Diagnosis

3.Preimplantation Genetic Testing Market, By Application:

Aneuploidy Structural Chromosomal Abnormalities Translocations Deletions Duplications Inversions Single Gene Disorders X-Linked Disorders HLA Typing Gender Identification

4.Preimplantation Genetic Testing Market, By Products And Services:

Reagents and Consumables Instruments Software and Services

5.Preimplantation Genetic Testing Market, By End User:

Maternity Centers & Fertility Clinics Hospitals, Diagnostic Labs, and Service Providers Research Laboratories & Academic Institutes

Request customization of the report @https://reportsglobe.com/need-customization/?rid=32828

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the Preimplantation Genetic Testing Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-preimplantation-genetic-testing-market/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

See more here:
Preimplantation Genetic Testing Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily...

A recently published size research report by Fact.MR on the Preimplantation Genetic Testing Size depicts a crystal clear view of the size over the considered period of assessment (2017 2022). The global preimplantation genetic testing size study comes with an all in all compilation of the future, existing, and historical outlook of the size as well as the factors bringing in such growth for the size. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities, and threats of each preimplantation genetic testing size player in a comprehensive way. Further, the preimplantation genetic testing size report emphasizes the adoption pattern of the preimplantation genetic testing across various industries.

The existing trends, restraints, opportunities, and size drivers are studied thoroughly to offer a clear, 360-degree understanding of the existing landscape prevailing in the preimplantation genetic testing size. The research paints a detailed picture of how the size is likely to take shape in the coming years given the influence of current drivers, opportunities, and restraints. In this latest size research study published by Fact.MR, the analysts have taken into account the preimplantation genetic testing size from a local as well as global viewpoint.

Act Today to Succeed Tomorrow, Know the COVID-19 Impact, Request for Sample @https://www.factmr.com/connectus/sample?flag=S&rep_id=292

The outbreak of novel coronavirus across the globe has changed the way about how we do business, it has resulted in both disadvantages and advantages for players operating in the preimplantation genetic testing size. A health crisis of enormous proportion, COVID-19 has emerged as a pandemic that would cause a restructuring of the world economy as well as social order. This outbreak is clearly going to characterize the coming era with fundamental schism. Many companies have shifted from their traditional methods of advertising during the lockdown period.

Taking help of this latest offering on the preimplantation genetic testing size by Fact.MR, the size players, suppliers, distributors, and other stakeholders can formulate innovative strategies based on their understanding of the pandemic and our report to expand their business and widen their base of customers. This research study by Fact.MR is likely to detail the factors that could impact the sales of products/ services in the global size landscape. The report is also likely to suggest avenues of growth that could boost sales in the post-pandemic era.

According to the size research report, the preimplantation genetic testing size is estimated to register a CAGR growth of 8.4% over the assessment period due to several key factors that is likely to influence the size, such as favorable regulatory policies, augmented spending on research and development. The analysts at Fact.MR makes use of the latest research methodologies while gathering data from credible and reliable sources, both primary and secondary, to prepare and present the size study.

In this preimplantation genetic testing size study, the following years are considered to project the size footprint:

The preimplantation genetic testing size report has answers to important questions, which include the following:

The preimplantation genetic testing size report covers the following regions:

On the basis of product type, the preimplantation genetic testing size report considers the following segments:

On the basis of end-use, the preimplantation genetic testing size report includes:

Ask for Regional Data of This Report @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=292

Prominent preimplantation genetic testing size players covered in the report contain:

The behavioral pattern of each of the size player, such as acquisitions, new product launches, partnerships, and mergers have been thoroughly studied to offer a detailed view of the competitive landscape of the preimplantation genetic testing size.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

SIZE ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Press Release:

Here is the original post:
Preimplantation Genetic Testing Size Size to Expand Lucratively during the Forecast Period 2017-2022 - The Cloud Tribune

(UroToday.com) Since 2015, multiple studies together have suggested that approximately a quarter of metastatic castration-resistant prostate cancer (mCRPC) tumors have mutations in DNA damage repair (DDR) genes. These alterations, especially those in genes for homologous recombination repair (HRR), are associated to varying degrees with response to PARP inhibitor therapy. Two PARP inhibitors are now approved for the care of patients with mCRPC and mutations in certain HRR genes: olaparib (based on PROfound trial) and rucaparib (based on TRITON2 trial). Given the significance of alterations in HRR genes in mCRPC, genomic testing for HRR alterations has been included in mCRPC treatment guidelines with the purpose of guiding genetic counseling and therapy selection.

In this poster, Dr. Neal Shore and colleagues describe real-world patterns and predictors of tissue testing for alterations in HRR genes. They focused on the community cancer care setting. Data were collected from the Flatiron Health Electronic Health Record derived database that was collected between 2013 and March 2019, prior to the approval of PARP inhibitor therapy in mCRPC, and focused on testing for alterations in BRCA1, BRCA2, ATM, CDK12, FANCA, and PALB2). The Flatiron database contains information on patient demographics, prostate cancer characteristics, and treatment, as well as genetic testing results.

From the Flatiron database, 5,213 patients with mCRPC were identified, 91% of which were managed at community oncology care centers. Of these patients, 674 (12.9%) underwent testing for the specified HRR gene alterations. Patient characteristics are shown below.

The breakdown of the 674 patients by testing method and number of genes tested is shown below.

BRCA1 and BRCA2 were the most commonly tested genes. A substantial portion of patients underwent only blood/saliva testing (40.5%, capable of detecting germline or circulating tumor DNA) or tumor-tissue testing only (42.1%, capable of detecting germline or tumor tissue DNA alterations). Only 1.8% of patients undergoing blood/saliva testing were tested for all 6 HRR genes, and 69% of tumor-tissue testing covered all 6 genes. Amongst the 286 patients who had negative blood/saliva testing, only 12.6% underwent tumor-tissue profiling, and 5 of these patients (13.9%) had an HRR alteration found.

The most common testing platform utilized was Foundation Medicine, followed by Guardant. Testing rates and the inclusion of more genes increased with time.

The prevalence of HRR alterations found is shown below.

Treatment at an academic medical center or having received multiple prior lines of therapy was associated with a higher likelihood of having HRR mutational profiling. Older age and higher PSA value at diagnosis of mCRPC were significantly associated with a lower likelihood of HRR mutation profiling.

The poster concludes that rates of HRR mutational testing did not increase dramatically with changes to the NCCN guidelines recommending this testing in 2017. Increased awareness of recommendations for testing, especially with the approval of two therapeutic agents contingent upon the presence of HRR alterations, is critical for the care of patients with mCRPC.

Presented by: Neal Shore, MD FACS, Urologist, and Director of the Carolina Urologic Research Center, Myrtle Beach, South Carolina

Written by: Alok Tewari, MD, Ph.D., Medical Oncologist at the Dana-Farber Cancer Institute, at the 2020 European Society for Medical Oncology Virtual Congress (#ESMO20), September 19th-September 21st, 2020

Excerpt from:
ESMO Virtual Congress 2020: Real-World Patterns of Genomic Testing in Patients with Metastatic Castration-R... - UroToday